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Abstract
The inhibition of death-receptor apoptosis is a conserved viral function. The murine cytomegalovirus (MCMV) gene M36 is a
sequence and functional homologue of the human cytomegalovirus gene UL36, and it encodes an inhibitor of apoptosis
that binds to caspase-8, blocks downstream signaling and thus contributes to viral fitness in macrophages and in vivo. Here
we show a direct link between the inability of mutants lacking the M36 gene (DM36) to inhibit apoptosis, poor viral growth
in macrophage cell cultures and viral in vivo fitness and virulence. DM36 grew poorly in RAG1 knockout mice and in RAG/IL-
2-receptor common gamma chain double knockout mice (RAGcC2/2), but the depletion of macrophages in either mouse
strain rescued the growth of DM36 to almost wild-type levels. This was consistent with the observation that activated
macrophages were sufficient to impair DM36 growth in vitro. Namely, spiking fibroblast cell cultures with activated
macrophages had a suppressive effect on DM36 growth, which could be reverted by z-VAD-fmk, a chemical apoptosis
inhibitor. TNFa from activated macrophages synergized with IFNc in target cells to inhibit DM36 growth. Hence, our data
show that poor DM36 growth in macrophages does not reflect a defect in tropism, but rather a defect in the suppression of
antiviral mediators secreted by macrophages. To the best of our knowledge, this shows for the first time an immune evasion
mechanism that protects MCMV selectively from the antiviral activity of macrophages, and thus critically contributes to viral
pathogenicity in the immunocompromised host devoid of the adaptive immune system.
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Introduction
The viral inhibition of programmed cell death is a conserved
function in animal viruses [1–4]. Both autophagy and apoptosis
are controlled by most DNA viruses, and frequently this is done by
redundant gene products. The herpes simplex gene ICP34.5 and
the cytomegalovirus (CMV) gene TRS1 both bind the host gene
Beclin and thus block autophagy [5,6]. Similarly, both the human
CMV (HCMV) and the murine CMV (MCMV) encode viral
genes that block mitochondrial apoptosis [7,8] by blocking Bax,
but not Bak signaling [7,9]. The HCMV gene has been termed
viral Inhibitor of Mitochondrial Apoptosis (vMIA), and corre-
sponds to exon 1 of the viral gene UL37 (UL37x1), whereas M38.5
is the MCMV counterpart. While the two genes show no sequence
homology, they occupy essentially the same position in the viral
genome and exert the same function at the molecular level,
arguing for the importance of this function. An even more
remarkable conservation of gene function has been observed in the
case of the viral Inhibitor of Caspase-8 Activation (vICA), encoded
by the HCMV gene UL36, and its counterpart in the MCMV
genome, a gene called M36 [10,11]. The UL36 and M36 genes
show conserved sequence homology, and both block death-
receptor apoptosis by binding to caspase-8 [10,11]. Interestingly,
MCMV lacking the M36 gene (DM36) could not grow to high
titers in macrophage cell lines or in primary macrophages, but
showed no loss of fitness in fibroblasts [10], which is in line with
the observations that UL36 is required for HCMV growth in
macrophages derived from THP-1 monocytes [12], but not for its
growth in fibroblasts [13].
Experiments in tissue culture systems and in vivo demonstrated
that the inhibition of apoptosis by viral gene products is a
determinant of viral fitness [12,14,15]. In the case of the UL36
gene, it has been shown that the inhibition of caspase signaling by
the pan-caspase inhibitor carbobenzoxy-valyl-alanyl-aspartyl-[O-
methyl]- fluoromethylketone (z-VAD-fmk) restores growth of
deletion mutants in immature, but not in mature macrophages
[12], indicating that apoptosis limits the replication of the UL36-
deficient virus in defined cell types. On the other hand, z-VAD-
fmk completely rescued the growth of the M36-deficient mutant in
murine macrophages [14]. We previously showed that the lack of
the viral gene M36 results also in severe growth deficits in vivo
[14,16], which could be rescued by the replacement of the M36
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gene with a dominant-negative variant of the Fas-associated via
Death Domain (FADDDN) gene, inserted into the viral genome
[14]. Therefore, apoptosis was shown to be a determinant of
MCMV fitness in macrophages and in vivo, arguing that the viral
replication in macrophages might be a key determinant of viral
fitness, but a direct demonstration for this assertion remained
pending. Moreover, it remained unclear if viral inhibition of
apoptosis plays a role in viral fitness in the immunocompromised
host, or merely in the immunocompetent one. This question may
be of key clinical relevance, as CMV infection results in overt
disease in the immunocompromised and rarely in the immuno-
competent host. Finally, it remained unclear why the inhibition of
caspase-8 plays an important role in viral fitness in macrophages,
but not in other cell types.
We show here that the M36-mediated block of apoptosis is not a
determinant of viral tropism for macrophages, but rather a
function enabling viral growth by protecting infected cells from
macrophage-secreted TNFa. Moreover we show that the viral
inhibition of death-receptor apoptosis is a key determinant of viral
growth and virulence in the immunodeficient host. Finally, we
show that macrophages protect the immunodeficient host from a
virus mutant lacking the M36 gene. Since the inhibition of death-
receptor signaling is a molecular mechanism that is conserved in
all CMV species, we define here the viral inhibition of apoptosis as
a key molecular target for the development of novel antiviral
strategies protecting specifically the immunodeficient host from
CMV disease.
Results
M36 Is a Determinant of Virulence in RAG1 Knockout
Mice
We showed previously that the inhibition of death-receptor
apoptosis by the M36 gene is necessary for MCMV growth in
multiple organs of mice, and is particularly important for viral
growth in the salivary glands [14]. It remained unclear whether
M36 is also a determinant of virulence. Cytomegalovirus causes
clinical symptoms in immunodeficient hosts; therefore, an
experimental model of CMV pathogenicity requires the infection
of immunodeficient mice. We tested DM36 virulence in recombi-
nase activating gene 1 (RAG1) knockout mice, which are deficient
for B and T lymphocytes. The cytotoxic activity of CD8 T-cells
and the secretion of TNFa by activated CD8 and/or CD4 T-cells
have both the potential to induce death-receptor apoptosis in
virus-infected cells. We reasoned that the lack of these functions in
RAG12/2 mice may contribute to their inability to control viral
growth. In that case, the growth and virulence of DM36 MCMV,
which is unable to block death receptor apoptosis, would be
rescued in RAG12/2 mice. Upon intravenous (i.v.) infection, we
observed an unexpected delay in the loss of body weight and
subsequent mortality of DM36 infected mice (Figure 1A). The
same observation could be made in intraperitoneally (i.p.) infected
mice (Figure 1B). Even more remarkably, subcutaneous (s.c.) or
intranasal (i.n.) infection with DM36 resulted in no significant
morbidity or mortality up to 4 months post infection, whereas all
mice infected with the control virus M36rev MCMV died by day
40 post infection (Figure 1C, 1D). Therefore, while systemic
administration of DM36 resulted in a delayed mortality compared
to the revertant virus, mucosal or local administration resulted in
significantly lower mortality and morbidity of mice infected with
the same virus.
M36-Mediated Block of Apoptosis Is a Determinant of
Viral Fitness and Virulence in RAG1 Knockout Mice
The M36 gene is an inhibitor of death-receptor mediated
apoptosis [10], and we showed that the block of apoptosis is a
determinant of viral in vivo fitness [14]. Therefore, it was conceivable
that the loss of virulence was due to poor viral replication caused by
an increase in apoptosis. This was tested by infecting mice with a
recombinant lacking the M36 gene, but carrying a dominant-
negative FADD gene (DM36-FADDDN), which replaced the anti-
apoptotic function of M36 in cells infected with the recombinant
virus. Mice infected with the viruses expressing the FADDDN gene
died essentially at the same time as the M36rev infected mice
when the infection was performed i.p. (Figure 2A) and with a
moderate delay upon s.c. infection (Figure 2B), yet even DM36-
FADDDN mice showed 100% mortality upon infection. At day
13 post infection, we observed a complete rescue of the virus
titer in spleen, lungs, and salivary glands (Figure 2C), strongly
arguing that the inhibition of death-receptor apoptosis is
required for MCMV replication in RAG12/2 mice, and
MCMV virulence in immunocompromised hosts. Analysis of
virus titer in various organs at 1, 2 or 3 months post s.c.
infection confirmed that DM36 MCMV is not present in the
lungs or salivary glands after approximately four weeks, but also
revealed that low levels of replicative virus are still detectable in
the spleen of some DM36 MCMV infected mice for up to 90
days post infection (Figure S1).
M36 Promotes Viral Growth in Mice Lacking B, T and NK
Cells
Death-receptor apoptosis inhibited DM36 growth in RAG12/2
mice (Figure 2C). Since these mice lack cytotoxic T-cells, we
assumed that another cell type may inhibit DM36 growth by
inducing apoptosis of DM36 infected cells through the death-
receptor. We considered the possibility that T-cells and NK cells
may control the virus in a redundant fashion and therefore
infected mice lacking B, T and NK cells due to targeted deletions
of the IL-2-receptor common gamma chain and of the RAG2
gene (RAGcC2/2 mice). Three days following i.p. injection the
infectious DM36 titer was marginally higher in the spleen, liver,
Author Summary
The majority of adult people are infected with human
cytomegalovirus (CMV), but in hosts with a healthy
immune system it is kept in check and does not cause
disease. On the other hand, in patients suffering from
innate or acquired immune deficiencies, CMV can cause
severe disease or death. Infection of mice with the mouse
CMV (MCMV) is an experimental model to study the
biology of CMV infection, and mice that lack all of their
lymphocytes are very susceptible to MCMV and die
typically within three weeks of infection. In this article
we show that MCMV causes disease and death in mice
lacking lymphocytes because its gene M36 blocks pro-
grammed cell death, or apoptosis. MCMV lacking the M36
gene grew thousand folds less well in these mice, which
significantly improved survival. This was because M36
deletion made MCMV susceptible to the action of
macrophages, cells that secrete soluble factors that induce
apoptosis. Importantly, viral growth and virulence of the
M36-deficient MCMV could be restored by blocking
apoptosis by other means, showing that the block of
apoptosis was critical for viral replication. Therefore, our
data imply that viral inhibition of apoptosis may be a key
molecular target for antiviral strategies in immunodeficient
hosts.
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and lungs of RAGcC2/2 mice than in the organs of RAG12/2
mice, but this increase was not specific for the mutant virus,
because we observed a similar increase in the titer of M36rev
MCMV (Figure 3A). This was in line with our observations that
RAGcC2/2 mice survived much longer when infected with
DM36 MCMV than with M36rev (Figure S2A), in accordance
with our results from RAG12/2 mice. The results were essentially
identical in RAG12/2 mice depleted of NK cells by continuous
treatment with anti-Asialo-GM1 antibodies before and after
infection with MCMV viruses (Figure S2B). Therefore, our data
indicated that NK cells were not crucial in the control of DM36 in
vivo growth, but rather that other cells of the innate immune
system contributed to the control of DM36 replication through a
death-receptor mediated mechanism.
Macrophage Depletion Rescues DM36 Growth in RAG12/2
and RAGcC2/2 Mice
We next considered that macrophages may be important in the
control of DM36 growth, because it has been shown that DM36
MCMV has a macrophage-specific growth defect [10]. Therefore,
we depleted macrophages in RAG12/2 and RAGcC2/2 mice by
i.p. injection of liposome encapsulated clodronate [17,18]. A
strong but not complete macrophage depletion was confirmed by
flow cytometry in spleen and the peritoneal cavity, whereas the
Figure 1. DM36 MCMV applied locally is avirulent in RAG12/2 mice. RAG12/2 mice were infected by (A) intravenous, (B) intraperitoneal, (C)
subcutaneous, or (D) intranasal administration with 105 PFU of DM36 (#) or M36rev (N) MCMV (n= 6–15/group) and monitored for weight loss and
survival. Mortality also includes mice that were sacrificed because they had lost more than 20% of body weight.
doi:10.1371/journal.ppat.1003062.g001
Block of Apoptosis Protects MCMV from Macrophages
PLOS Pathogens | www.plospathogens.org 3 December 2012 | Volume 8 | Issue 12 | e1003062
depletion was less efficient in the liver (Figure S3). We could
observe that macrophage depletion rescued DM36 growth in
spleen and lungs, almost to levels seen in mice infected with the
revertant virus whereas the rescue was not as pronounced in the
liver (Figure 3B), consistent with the less efficient macrophage
depletion. Therefore, our data indicated that M36 allows MCMV
growth in the presence of macrophages.
Zymosan and IFNc Impair DM36 Growth in Primary MEF,
but Not in 3T3 Fibroblasts
To study the mechanism by which macrophages limit DM36
MCMV growth, we turned to cell culture conditions that
contained mixtures of macrophages and other cell types.
Preparations of primary mouse embryonic fibroblast (MEF) cells
consistently contain a fraction of CD11b positive cells which are
absent from 3T3 fibroblast cell lines (Figure S4). Testing the
induction of apoptosis in MEF cells infected with DM36 MCMV,
resulted in a significant increase in the fraction of cells expressing
the activated isoform of caspase-3, a marker of apoptosis, over the
M36rev- or mock-infected controls, which was dependent on the
presence of CD11b positive cells (Figure 4A). This was in contrast
with our previous observations that fibroblast cell lines do not
undergo apoptosis upon DM36 infection, unless stimulated with
anti-FAS antibodies [10]. Since DM36 induced apoptosis in
primary MEF cells, we compared DM36 to M36rev MCMV
growth in primary MEF cells and NIH-3T3 fibroblasts. To test if
macrophages need to be activated to control the virus growth, we
activated them by administering IFNc, Zymosan (a toll-like
receptor 2 agonist), or both of these mediators in combination to
the infected cells. We observed no significant difference in DM36
and M36rev titers when the cells were infected in absence of
stimuli which may activate macrophages, but a substantial
reduction of DM36 titer in the presence of IFNc and Zymosan.
The combination of IFNc and Zymosan resulted in a 100-fold
reduction of DM36 proliferation in MEF cells, but had no effect in
NIH-3T3 cells (Figure 4B). This was consistent with a dramatic
increase in apoptosis of DM36 infected cells upon combined
treatment with IFNc and Zymosan (Figure 4C). Similarly,
addition of LPS and IFNc suppressed DM36 growth to the same
extent, indicating that the antiviral action was not exclusive to
TLR2 activation (Figure S5). Interestingly, the reduction in virus
titer could only be observed when cells were infected at a
multiplicity of infection (MOI) below 0.1, but not at higher MOIs
(data not shown). Z-VAD-fmk, a pan-caspase inhibitor, rescued
DM36 growth in MEF cells treated with Zymosan and IFNc to
levels seen in M36rev (Figure 4D), arguing strongly that M36
improved MCMV dissemination on MEF cells by blocking
caspase signaling, which would be in line with the in vivo data
(Figure 2).
Figure 2. Apoptosis inhibition is required for viral dissemination to distant organs. RAG12/2 mice were (A) i.p. or (B) s.c. infected with
105 PFU of indicated virus and monitored for survival (n = 4–6/group). Mortality also includes mice that were sacrificed because they had lost more
than 20% of body weight. (C) Infectious virus was determined by plaque assay on MEF cells in spleen (top panel), lungs (middle panel), and salivary
glands (SG, bottom panel) of i.p. infected mice on day 13 after infection with 105 PFU of indicated virus. Each symbol represents an individual mouse.
Differences in median values are highlighted by grey shading. The dashed line shows the limit of detection.
doi:10.1371/journal.ppat.1003062.g002
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Macrophage Contaminants Impair DM36 Growth in
Primary MEF Cells
To directly test the role of macrophages in DM36 growth, we
depleted the CD11b positive cells from MEF cell preparations by
cell separation using anti—CD11b antibodies coupled to magnetic
beads and collected the cells from the unbound fraction. The
efficiency of the depletion was confirmed by flow cytometry for
CD11b, upon which the cells were infected and DM36 growth was
compared to M36rev in presence or absence of Zymosan and
IFNc. CD11b depletion resulted in a complete rescue of DM36
growth, even in the presence of Zymosan and IFNc (Figure 5A),
demonstrating that the poor growth was not due to intrinsic
differences between primary fibroblasts and fibroblast cell lines,
and strongly suggesting that CD11b positive cells are required for
the inhibition of DM36 growth.
To confirm that macrophages were necessary and sufficient to
control DM36 growth in a milieu containing Zymosan and
IFNc, we cocultivated the CD11b-depleted MEF cells with
increasing amounts of ANA-I macrophages, a macrophage cell
line. We could readily observe a suppression of DM36, but not
M36rev growth that was dependent on the percentage of
macrophages in cell culture (Figure 5B). While ANA-I cells at
higher concentrations suppressed DM36 growth even in the
absence of Zymosan and IFNc, the effect was more pronounced
in their presence (Figure 5B), consistent with our earlier data
(Figure 4B). Therefore, our data strongly argued that macro-
Figure 3. Macrophage, but not NK cell, depletion rescues DM36 MCMV in vivo. In a combined experiment to elucidate the role of (A) NK
cells and (B) macrophages in the control of DM36 MCMV growth, RAG12/2 and RAGcC2/2 mice received injections of 200 ml liposome encapsulated
(A) PBS or (B) clodronate 48 hours (i.v.) and 24 hours (i.p.) prior to viral infection. Following liposome injection mice were i.p. injected with 105 PFU
DM36 (#) or M36rev (N) MCMV (n= 4–5/group). At day 3 post infection infectious virus was determined by plaque assay on MEF cells in spleen (top
panels), lungs (middle panels) and liver (bottom panels). Each symbol represents an individual mouse. Differences in median values are highlighted
by grey shading. The dashed line shows the limit of detection. *p,0.05; **p,0.01.
doi:10.1371/journal.ppat.1003062.g003
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phages control the growth of DM36 in mixed populations of
cells.
IFNc Impairs DM36 Growth in Macrophage/Fibroblasts
Cocultures by Acting on Fibroblasts and Not on
Macrophages
The IFN type II receptor is present on both fibroblasts and
macrophages. Therefore, it was possible that IFNc suppressed
DM36 growth by acting on macrophages or on fibroblasts. To
define which scenario occurred, we prepared CD11b-depleted
cultures of primary MEF cells from mice lacking the IFN type II
receptor (IFNcRec2/2), or from the parental mouse strain, and
cocultivated the fibroblasts with bone marrow (BM)-derived
macrophages derived from IFNcRec2/2 mice or BM-derived
macrophages derived from the parental mouse strain (Figure 6A).
We observed a difference in the titers of DM36 and M36rev
regardless of the source of macrophages used in the cocultivation
assay (Figure 6B). On the other hand, DM36 growth was rescued
to revertant-levels in macrophage-depleted MEF cells from
IFNcRec2/2 mice, and here it was irrelevant whether we added
macrophages from IFNcRec2/2 mice or the parental mouse
strain (Figure 6B). Hence, our data showed that IFNc controlled
DM36 growth by acting on fibroblasts and not on macrophages.
TNFa Secreted from Activated Macrophages Impairs
DM36 Replication in Fibroblasts through a Caspase-
Dependent Mechanism
The mechanism by which macrophages blocked the growth of
DM36 in MEF cell preparations remained unclear. Macrophage
depletion did not result in a loss of M36rev titer, showing that viral
replication in the macrophage population was not a dominant
factor. Therefore, we hypothesized that activated macrophages
may block the growth of DM36 by releasing factors that inhibit
DM36 growth in fibroblasts. To test this, we treated ANA-I
macrophages with IFNc and Zymosan for 5 days and transferred
their supernatants on CD11b-depleted MEF cells infected with
DM36 or M36rev (Figure 7A). To elucidate the contribution of the
virus infection to the macrophage activation, we infected the
macrophages at a MOI of 1 with DM36, M36rev or mock-infected
them in the presence of Zymosan and IFNc. Supernatants were
filtered using a 100 nm filter to prevent carryover of virus from
ANA-I supernatants into MEF cultures (Figure 7A). We observed
Figure 4. Apoptosis of primary MEF cells inhibits DM36 growth. (A) MEF cells and MEF preparations depleted of CD11b positive cells (MEF
DCD11b) were infected with indicated virus at a MOI of 1, and 24 hours later analyzed for the induction of the active isoform of caspase-3 by flow
cytometry. The percentage of caspase-3 positive cells in a representative experiment is indicated. (B) MEF or NIH-3T3 cells were infected at a MOI of
0.03 with DM36 (white bars) or M36rev (grey bars) and supernatants were titrated for infectious MCMV titer at day 4 post infection. Where indicated,
Zymosan (30 mg/ml) and/or IFNc (100 ng/ml) were added to the supernatant immediately following infection. Histograms indicate means from three
experiments, error bars are standard deviations. (C) MEF cells were infected at a MOI of 5 with DM36, M36rev or mock-infected. Where indicated, IFNc
(100 ng/ml) and Zymosan (30 mg/ml) were added to the supernatant immediately following infection. Expression of the active isoform of caspase-3
was measured 24 hours post infection by flow cytometry and the percentage of caspase-3 positive cells in the total cell pool is indicated. (D) MEF
cells were infected at a MOI of 0.03 with DM36 (white bars) or M36rev (grey bars) and supernatants were titrated for infectious MCMV at day 4 post
infection. Where indicated, z-VAD-fmk (33 mM), Zymosan (30 mg/ml) and IFNc (100 ng/ml) were added to the supernatant immediately following
infection. Histograms indicate means from three experiments, error bars are standard deviations, * p,0.05.
doi:10.1371/journal.ppat.1003062.g004
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DM36 growth reduction in cells treated with ANA-I derived
supernatant, but not in control cells grown in normal medium
(Figure 7B). Moreover, we could see that it was irrelevant if the
macrophage cultures were infected with virus or not, showing that
the impact of the ANA-I supernatant on DM36 growth was due to
effects on fibroblasts (Figure 7B). Z-VAD-fmk treatment of MEF
cells promptly rescued the DM36 growth to WT levels, indicating
that the mechanism of action was caspase-dependent (Figure 7B).
Since TNFa is a factor that is secreted from activated
macrophages, and has the ability to induce apoptosis in target
cells by a caspase-8 dependent signaling pathway, we considered
the possibility that macrophages control DM36 by secreting
TNFa. Therefore, we added neutralizing antibodies against TNFa
to the ANA-I supernatant used in wells infected with DM36 or
M36rev. We observed that anti-TNFa antibodies rescued the
growth of DM36 in fibroblasts (Figure 7B). Therefore, our data
strongly indicated that TNFa secreted from macrophages is
necessary to control DM36 growth in fibroblasts.
Discussion
In vitro DM36 MCMV growth is known to be attenuated in
macrophages, which was due to viral inhibition of caspase
signaling, and appeared to be particularly dependent on the
death-receptor signaling pathway [10,14]. Similarly, the mu-
tant was attenuated in vivo [16] due to poor viral inhibition of
Figure 5. DM36 grows poorly in the presence of macrophages. (A) CD11b positive cells were removed from MEF cell preparations by
monoclonal antibodies coupled to magnetic beads, upon which the cells were infected with DM36 (white bars) or M36rev (grey bars), alone or in the
presence of Zymosan (30 mg/ml) or IFNc (100 ng/ml). Virus titer in the supernatant of cells depleted of macrophages was compared to macrophage-
undepleted MEF preparations at day 4 post infection. (B) Upon macrophage depletion, primary fibroblasts were cultured with indicated amounts of
ANA-I macrophages (MW), in the presence or absence of Zymosan (30 mg/ml) and IFNc (100 ng/ml). Infectious virus titer in supernatants was
established at day 4 post infection. Histograms indicate mean values from three separate experiments, error bars show standard deviation, * p,0.05.
doi:10.1371/journal.ppat.1003062.g005
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death-receptor signaling [14]. However, it remained unclear if
the viral inability to grow in macrophages contributed to its in
vivo attenuation. Poor DM36 in vivo growth was related to its
macrophage phenotype, but surprisingly, not as a result of a
defect in tropism for macrophages. Instead we observed that
DM36 MCMV does not only grow poorly in macrophage
populations, but also in their mere presence. In fact, DM36
grew poorly because it could not counter the antiviral factors
secreted by macrophages. While our results do not formally
exclude the possibility that M36 additionally acts as a tropism
factor in macrophages, for instance by functions unrelated to
apoptosis, our data argue strongly that the inability of a CMV
variant to grow in a cell type does not necessarily reflect a lack
of tropism. This finding might bear relevance for other viruses
where tropism has been experimentally validated by the virus
ability to grow in pure cultures of a defined type. For instance,
the tropism of varicella-zoster virus for T-cells or adenovirus
tropism for hematopoietic cells have both been linked to viral
genes that inhibit apoptosis [4,19]. We postulate here that the
secretion of death-receptor ligands from infected cells may act
in a paracrine fashion and in a cell-type unrestricted manner.
Therefore, the viral inhibition of the death receptor pathway
may mask as a determinant of tropism, while reflecting an
immune evasion mechanism that rescues the virus from the
antiviral action of cells of a specific type. Future studies will
clarify to which extent this observation can be generalized to
other viruses.
It has been previously shown that M45, another MCMV-
encoded anti-apoptotic gene [20], is necessary for viral growth in
immunodeficient SCID mice [21]. However, it remained unclear
if this was due to the anti-apoptotic function of the M45 gene, or to
some other property encoded by the same gene, for instance its
ability to block NF-kB signaling [22]. We show here that the
pathogenicity of MCMVs expressing M36 is directly related to
their ability to block death-receptor apoptosis, because the
virulence and the viral replication in the immunodeficient host
could be rescued by the replacement of M36 with another gene
blocking the same signaling cascade.
McCormick et al. recently showed that the HCMV gene
UL36 blocks apoptotic and non-apoptotic cell death in mature
THP1 cells infected with HCMV [12]. While our data showed a
clear role for the M36-mediated inhibition of apoptosis, our
results cannot formally exclude the possibility that M36 may
also affect other functions important for viral replication. This
would be particularly important in line of recent observations
that caspase-8 signaling suppresses RIP1/RIP3-dependent
Figure 6. IFNc controls DM36 growth by acting on the IFNc receptor on fibroblasts, not on macrophages. (A) Experimental setup: MEF
cells depleted for CD11b positive cells (MEF DCD11b) and BM-derived macrophages (BMM) were obtained from IFNcRec2/2 (IFNcR2/2) or wild-type
(WT) mice and cocultured (10% of macrophages, 90% of fibroblasts in cell culture) in all possible combinations. Cells were infected with DM36 or
M36rev in the presence of Zymosan (30 mg/ml) and IFNc (100 ng/ml) and virus titer in the supernatants was established at day 4 post infection. (B)
Infectious titer of DM36 (white bars) or M36rev MCMV (grey bars) is shown as mean+standard deviation from three independent experiments. The
combination of cells used in the infectious experiment is indicated below the x-axis, * p,0.05.
doi:10.1371/journal.ppat.1003062.g006
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necrotic or necroptotic cell death pathways [23] and that the
suppression of this pathway by the MCMV gene M45 [24,25]
plays a crucial role in viral in vivo growth [24]. Hence, the
modulation of caspase-8 signaling by M36 may also have effects
on RIP1/RIP3-dependent pathways, and it remains unclear if
the M36-mediated block of the caspase-8 dependent apoptotic
pathway results is a similar block of caspase-8 effects on non-
apoptotic cell death. Therefore, more work is needed to clarify
the role of M36/UL36 on the RIP1/RIP3 pathway.
It has been shown that macrophages play an important role
in the control of in vivo MCMV replication [26,27], yet the
exact mechanism of their antiviral action remained unclear. We
show here that apoptosis plays an important role in the antiviral
macrophage activity, because mice that lacked both NK and T-
cells but contained macrophages controlled DM36 MCMV
much more efficiently than the revertant, but macrophage
depletion rescued DM36 in these mice to titers that almost
matched those seen in the infection with the revertant virus.
While our data do not exclude the possibility that DM36 was
controlled by redundant antiviral activity from NK, CD8 T-
cells and macrophages, they clearly indicated that macrophages
were sufficient for the in vivo control of DM36. Conversely, M36
was necessary for viral replication and virulence in the
immunocompromised host lacking T-cells or NK and T-cells,
because it allowed the virus to overcome the antiviral activity of
macrophages. This finding may also have clinically relevant
consequences, because most CMV-related disease occurs in
immunocompromised patients and not in the immunocompe-
tent ones. Therefore, the inhibition of death-receptor apoptosis
might be a virulence factor that would affect CMV pathogen-
esis specifically in the absence of a mature or functional
adaptive immune system.
Macrophage depletion in mice did not result in a complete
rescue of DM36 growth to titers seen upon infection with the
revertant. This result may indicate that there may be additional
cell types which also contribute to the selective in vivo control of
DM36 MCMV growth, or it may be due to the fact that the
macrophage depletion was not 100% efficient, and that the
small fraction of macrophages spared from the treatment with
liposome encapsulated clodronate was sufficient to affect
selectively DM36 growth. This is both consistent with observa-
tions that treatment with liposome encapsulated clodronate does
not allow for a complete depletion of macrophages resident in
solid organs [28], and our observations that a fraction of 1% of
macrophages could affect the growth of DM36 in tissue culture
(Figure 5B).
Figure 7. TNFa secreted from macrophages synergizes with IFNc to impair DM36 growth by a caspase-dependent mechanism. (A)
Experimental setup: ANA-I cells were treated for 5 days with Zymosan and IFNc in the presence of DM36 MCMV, M36rev MCMV, or no virus, upon
which the supernatants were filtered to prevent virus carryover and transferred to CD11b-depleted MEF cells infected with DM36 or M36rev. (B)
Infectious titer of DM36 (white bars) or M36rev-MCMV (grey bars) at 5 days post infection. Legends below the x-axis indicate the medium used during
infection – control medium (DMEM), supernatant from ANA-I cells infected with DM36, M36rev or no virus (MOCK). Where indicated, the ANA-I
supernatant was supplemented with neutralizing anti-TNFa (1 mg/ml) antibodies or z-VAD-fmk (33 mM). Histograms indicate mean values from three
separate experiments, error bars show SD, * p,0.05.
doi:10.1371/journal.ppat.1003062.g007
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Interestingly, we could observe that the in vitro antiviral activity
of macrophages was entirely dependent on a costimulation with
IFNc (Figure 4B, Figure 6). Hence, TNFa was necessary, but not
sufficient, to control viral growth in vitro. We showed previously
that TNFa is neither necessary, nor sufficient to control DM36
MCMV in vivo, because the mutant remained attenuated in TNFR
KO mice [14]. The difference between our current in vitro
evidence, and the former in vivo results, is consistent with a model
where TNFa, Fas-ligand or the Trail-ligand activate the death-
receptors in a redundant fashion, but merge at the FADD level,
which is also in line with the observation that DM36 could not be
rescued in FAS2/2 or TNFRp552/2 mice, but was rescued by
FADDDN [14]. While the synergic anti-CMV activity of TNFa
and IFNc is well described in literature [29,30], it was not clear, to
the best of our knowledge, that this activity critically depends on
caspase signaling. It remains unclear if M36 may also contribute to
the protection of the virus from cytokines secreted by NK cells,
CD8 T-cells or Th1 CD4 T-cells. Our data would suggest that
M36 may protect the virus against multiple effector mechanisms.
We propose a model of action, where activated macrophages
secrete TNFa which synergizes with IFNc in fibroblasts to block
virus growth, yet M36, by blocking a caspase-dependent
mechanism prevents apoptosis and rescues the virus growth
(Figure 8). We demonstrated that macrophages control specifically
DM36 growth in vivo and that the viral in vivo growth and virulence
was critically dependent on death-receptor signaling. Therefore,
we postulate that M36/UL36 may present excellent targets for
antiviral therapies.
Materials and Methods
Ethics Statement
All animal experiments were performed in compliance with the
German animal protection law (TierSchG BGBl. S. 1105;
25.05.1998). The mice were housed and handled in accordance
with good animal practice as defined by FELASA and the national
animal welfare body GV-SOLAS. All animal experiments were
approved by the responsible state office (Lower Saxony State
Office of Consumer Protection and Food Safety) under permit
number 33.9-42502-04-11/0426.
Mice
RAG12/2 and RAGcC2/2 mice were bred at the Helmholtz
Centre for Infection Research (Braunschweig, Germany). BALB/c
mice were purchased from Janvier (Le Genest Saint Isle, France).
Cells
M2-10B4 (ATCC; catalog no. CRL-1972) cells were main-
tained in Dulbecco’s modified minimal essential medium (DMEM)
supplemented with 10% fetal calf serum (FCS), L-glutamine and
penicillin/streptomycin. ANA-I and NIH-3T3 cells were grown as
described previously [14]. C57BL/6, 129SV2 and IFNcRec2/2
(on an 129SV2 background) murine embryonic fibroblasts (MEFs)
were prepared and maintained as described previously [31].
Primary bone-marrow macrophages were isolated and grown by
standard procedures, essentially as described elsewhere. In brief,
cells from the cavities of both tibial bones were flushed in 5 ml
Figure 8. Diagram of the proposed mechanism of action. Activated macrophages secrete TNFa (and possibly additional cytokines) which
synergize with IFNc in fibroblasts to block virus growth by a mechanism that is dependent on caspase signaling. M36 blocks the caspase-dependent
signaling pathway and thus prevents apoptosis and rescues the virus growth.
doi:10.1371/journal.ppat.1003062.g008
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PBS, briefly spun down and resuspended by pipetting them up and
down in DMEM supplemented with 10% FCS. One quarter of
total cells from one mouse was layered in a 10-cm Petri dish, in
medium supplemented with 10 ng/ml of recombinant murine
macrophage-colony stimulating factor (M-CSF, Sigma, catalog
no. M9170). Two days later, the non-adherent cells were
discarded, and medium with fresh M-CSF was added. Macro-
phages were harvested 7 days post isolation and used in
experiments as detailed elsewhere.
Viruses
The viruses used in this study, MCMV-M36rev (briefly
M36rev), MCMV-DM36 (DM36) and FADDDN overexpressing
viruses, have been described previously by Cicin-Sain et al. [14]
and Menard et al. [10]. Virus stocks were generated on M2-10B4
cells and quantified by plaque assay on MEFs as described
previously [10,31].
Flow Cytometry
MEF cells from a 6-well plate were harvested by trypsination
and stained for 30 minutes with a 1:40 dilution of purified a-
CD16/32 antibodies to block the Fc receptor and avoid unspecific
staining. Following that, cells were stained with a 1:100 dilution of
a-CD11b-TRICOLOR (Invitrogen) or a-CD11c-PE (Invitrogen)
antibodies in 100 ml PBS, 2% FCS, upon which the cells were
washed in 5 ml of PBS and analyzed in an EPICS XL flow
cytometer (Beckmann Coulter). MEF cells were stained for the
active isoform of caspase-3 exactly as previously described [14].
In Vitro Macrophage Depletion
Approximately 107 MEF cells were trypsinized, washed and
resuspended in DMEM without FCS, supplemented with 5 mg of
biotinylated a-CD11b antibodies for 30 minutes on ice (or
incubated with no antibodies for control groups). Both test and
control cells were washed, resuspended in 6 ml DMEM supple-
mented with 150 ml of Streptavidin-conjugated magnetic beads
(Dynal) and incubated at 4uC on a slow moving rotor for
20 minutes. Cells were then placed on a magnetic column (Dynal)
for 2 minutes and non-adherent cells were carefully collected. The
procedure was repeated twice to increase cell purity, upon which
the cells were counted and the efficiency of the procedure was
tested on a 105 cell aliquot. Alternatively, macrophages were
depleted from MEF preparations using CD11b-conjugated micro
beads (Miltenyi Biotec) according to the manufacturer’s instruc-
tions. The rest of the cells were seeded in 24-well plates at 66105
cells per well, alone or in combination with macrophages, and
used in infection experiments as detailed below.
In Vitro Infection Experiments
Cells were spread on the day before infection in 24-well plates
and cells from one representative well were counted in a Neubauer
chamber on the day of infection. This typically resulted in a cell
count of 60 000 cells per well, hence we infected cells with
2000 PFU in a volume of 400 ml per well to obtain a MOI of 0.03
in our typical infection experiment. Upon 1 hour of incubation,
the virus was removed and medium replaced with fresh one.
Where indicated, the medium was replaced with medium
containing IFNc (Molecular Probes), Zymosan (Sigma), LPS
(Sigma), neutralizing a-TNFa antibodies (Sigma), or z-VAD-fmk
(R&D Systems), in the combinations shown for individual
experimental conditions. In the supernatant transfer experiment,
ANA-I macrophages were infected with indicated virus at a MOI
of 1 for 5 days, upon which the supernatant was filtered through a
0.1 mm pore-size filter (Millipore) and transferred to CD11b-
depleted MEF cells at 1 hour post infection with the indicated
virus.
In Vivo Infection Experiments
Adult male or female mice were infected with purified, tissue-
culture derived virus by subcutaneous injection into the hind leg
(total volume of 50 ml), by intraperitoneal or intravenous injection
(200 ml) or by intranasal inoculation under isoflurane anesthesia
(15 ml). At indicated time points after infection, organs were
dissected in sterile conditions and stored at280uC until use for the
plaque assay. Macrophage depletion was performed by i.v. and i.p.
injections of 200 ml of liposome encapsulated clodronate at 48 and
24 hours prior to viral infection, respectively. Age-matched
littermates were treated with liposome encapsulated PBS in the
same manner. Depletion of spleen, liver and peritoneal cavity
macrophages was confirmed by flow cytometry analysis on a
LSRII (BD Biosciences) using the following antibodies: F4/80-
FITC, CD11b-PE-Cy7 and Ly6C-APC (Biolegend). NK cell
depletion was performed by i.p. injection of 50 mg anti-Asialo-
GM1 antibody (eBioscience) 24 hours prior to virus infection. For
continued depletion of NK cells, administration of anti-Asialo-
GM1 antibody was repeated every seven days. NK cell depletion
was confirmed in splenocytes by flow cytometry analysis using
NKp46-PE antibody (Biolegend) (data not shown).
Plaque Assay
Organ homogenates were titrated on MEFs by plaque assay
[32] with modifications described previously [16]. In brief, organs
were homogenized in 5 ml of DMEM (supplemented with 5%
FCS) and diluted in 1:10 steps. For the determination of in vivo
titers, the diluted homogenates were layered on MEFs and
centrifuged at 10006 g for 30 minutes for enhancement of
infectivity, which was followed by 30 minutes of incubation at
37uC. For the titration of virus from experiments performed in
vitro, the centrifugation step was omitted, but the cells were
incubated with the virus for 1 hour at 37uC. In both cases, the
supernatants were replaced with an overlay of carboxymethylcel-
lulose (Sigma) to prevent secondary viral spread. Plaques were
counted four days later.
Statistical Analysis
Two experimental groups were compared using the Mann-
Whitney test and groups were considered significantly different if
the P value was ,0.05. In comparisons of more than two
experimental groups, the Kruskal-Wallis test with Dunn’s post-test
was applied. In vitro titers were compared by student t-test.
Supporting Information
Figure S1 DM36 MCMV applied subcutaneously is
persistent in spleens of immunocompromised mice.
(A) RAG12/2 mice were s.c. infected with 105 PFU of indicated
virus and monitored for survival (n = 4–6/group). Mice were
sacrificed at day 27 post infection, when the M36rev-infected
mice had lost more than 20% of body weight. Infectious virus was
determined by plaque assay on MEF cells in spleen, lungs, and
salivary glands. (B) Since virus was still detectable in spleens of
DM36-infected mice at day 27 post infection, new cohorts of
RAG12/2 mice were s.c. infected with 105 PFU of indicated
virus. At 1, 2 or 3 months post infection infectious virus was
determined by plaque assay on MEF cells in spleen. { - M36rev-
infected mice died by day 36 post infection. Each symbol
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represents an individual mouse. Differences in median values are
highlighted by grey shading. The dashed line shows the limit of
detection.
(TIF)
Figure S2 NK cells are not responsible for the DM36
MCMV growth defect in vivo. (A) RAGcC2/2 mice were s.c.
infected with 105 PFU of DM36 (#) or M36rev (N) MCMV (n=5/
group) and monitored for weight loss and survival. (B) NK cells
were depleted in RAG12/2 mice by i.p. injection of 50 mg anti-
Asialo-GM1 antibody. After 24 hours mice were s.c. infected with
105 PFU of DM36 (#) or M36rev (N) MCMV (n=9/group) and
monitored for weight loss and survival. c Mortality also includes
mice that were sacrificed because they had lost more than 20% of
body weight.
(TIF)
Figure S3 Macrophages are partially depleted from
RAG12/2 mice after treatment with liposome encapsu-
lated clodronate. RAG12/2 mice received i.v. and i.p.
injections of 200 ml liposome encapsulated PBS or clodronate
(Cl2MBP) at 0 and 24 hours. 24 hours following the second
injection, the mice were i.p. injected with 105 PFU of MCMV and
3 days later macrophage depletion was evaluated in (A) spleen, (B)
liver, and (C) the peritoneal cavity by flow cytometry analysis using
CD11b and F4/80 antibodies to identify macrophages and Ly6C
antibody to exclude monocytes. Representative gating of one out
of two tested animals per group is shown. Please note that the
optimal depletion was achieved in the spleen and peritoneal cavity,
but not in the liver. (D) The frequency of F4/80 positive cells
(bottom panel of A, B, and C, respectively) is given as percentage
of total cells and their reduction upon liposome encapsulated
clodronate treatment is expressed as fold change.
(TIF)
Figure S4 CD11b cells in primary MEF preparations.
Primary MEF cells or NIH-3T3 fibroblasts were trypsinized and
stained with anti-CD11b, anti-CD11c (control antibody) or no
antibodies. Typical flow-cytometric results are shown as dot blots,
where the specific staining is indicated on the y-axis, and the
numbers represent the percentage of cells above the indicated
threshold line.
(TIF)
Figure S5 LPS synergizes with IFNc and inhibits DM36
growth to the same extent as Zymosan. MEF cells were
infected with indicated virus in the presence of unsupplemented
DMEM (MOCK), or DMEM supplemented with LPS (100 ng/
ml) and IFNc (100 ng/ml) or Zymosan (30 mg/ml) and IFNc
(100 ng/ml). Four days later, infectious virus titer in supernatants
was established by plaque assay. Group means + standard
deviations are shown.
(TIF)
Figure S6 The presence of neutralizing TNFa antibodies
rescues DM36 growth in ANA-I macrophages. ANA-I (A)
or IC-21 (B) macrophages were infected at a MOI of 1 with
DM36, M36rev or mock-infected either in the presence or absence
of neutralizing TNFa antibodies (1 mg/ml). Virus titers in
supernatants were determined at day 3 post infection by plaque
assay.
(TIF)
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